SNY vs SYK
Sanofi vs Stryker Corporation — AI-powered side-by-side comparison
VS
SYK
Stryker Corporation
59
Buy
| Metric | SNY | SYK |
|---|
| AI Score |
66
|
59
|
| Price |
$45.63
|
$329.92
|
| P/E Ratio |
24.11×
|
33.98×
|
| ROE |
10.9%
|
14.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
72.8%
|
65.2%
|
| Debt / Equity |
0.34×
|
0.62×
|
| Dividend Yield |
5.2%
|
1.1%
|
| RSI (14) |
71.1
|
44.6
|
| Beta |
0.278
|
0.771
|
| Expected Upside |
+5.6%
|
+13.1%
|
AI Committee View
Current Innellis committee reasoning for SNY versus SYK.
SNY leads by 7 points.
SNY scores 66/100 (Buy) versus SYK at 59/100 (Buy).
SNY Committee View
67% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.28) -- balance sheet can absorb a shock. The main limiting factor is eps declining -37.4% yoy despite any revenue growth. The committee is constructive but not yet at full conviction.
Bull Case
- Price-to-book of 1.4x is a discount to asset value — Value
- Dividend yield of 4.1% pays you to wait — Value
- Revenue growing 39.5% YoY -- genuine top-line momentum — Growth
Bear Case
- EPS declining -37.4% YoY despite any revenue growth — Growth
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
SYK Committee View
60% agreement
5 analysts
Positive signals support the current rating — eps growing 27.7% yoy. The committee sees sufficient evidence to maintain the constructive view.
Bull Case
- ROE of 16.4% shows genuine earnings power backing the valuation — Value
- EPS growing 27.7% YoY — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- P/E of 35.2 is moderate-to-rich — Value
- Price-to-book of 6.0x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical